Danaher Co. (NYSE:DHR) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its stake in shares of Danaher Co. (NYSE:DHR) by 8.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,318,827 shares of the conglomerate’s stock after selling 1,987,430 shares during the quarter. Danaher makes up approximately 0.9% of Wellington Management Group LLP’s holdings, making the stock its 14th largest position. Wellington Management Group LLP owned approximately 2.98% of Danaher worth $4,893,737,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Howard Capital Management Group LLC lifted its position in Danaher by 4.1% in the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 48 shares during the last quarter. CreativeOne Wealth LLC raised its holdings in shares of Danaher by 24.7% during the third quarter. CreativeOne Wealth LLC now owns 1,542 shares of the conglomerate’s stock valued at $429,000 after buying an additional 305 shares during the last quarter. Public Sector Pension Investment Board boosted its position in shares of Danaher by 27.7% during the third quarter. Public Sector Pension Investment Board now owns 24,903 shares of the conglomerate’s stock worth $6,924,000 after buying an additional 5,400 shares during the period. Edgestream Partners L.P. grew its holdings in Danaher by 466.1% in the 3rd quarter. Edgestream Partners L.P. now owns 10,965 shares of the conglomerate’s stock worth $3,048,000 after buying an additional 9,028 shares in the last quarter. Finally, Bellevue Group AG increased its position in Danaher by 25.8% in the 3rd quarter. Bellevue Group AG now owns 105,590 shares of the conglomerate’s stock valued at $29,356,000 after acquiring an additional 21,670 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

DHR opened at $205.69 on Monday. The firm has a market capitalization of $147.01 billion, a P/E ratio of 38.96, a PEG ratio of 2.66 and a beta of 0.82. The stock has a fifty day moving average of $214.57 and a 200-day moving average of $236.39. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm posted $2.09 earnings per share. Equities analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is 24.24%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DHR. Wells Fargo & Company reduced their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Scotiabank initiated coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Jefferies Financial Group dropped their price target on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a report on Friday, December 13th. Finally, Guggenheim started coverage on Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $278.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.